This recombinant monoclonal antibody is a research-grade biosimilar to Anifrolumab-FNIA, designed to target interferon alpha and beta receptor subunit 1 (IFNAR1). IFNAR1 is a critical component of the type I interferon receptor complex, which mediates cellular responses to interferon-alpha and interferon-beta signaling. Upon ligand binding, IFNAR1 heterodimerizes with IFNAR2, initiating JAK-STAT signaling cascades that regulate immune responses, antiviral defense, and inflammatory processes. Dysregulated type I interferon signaling is implicated in various autoimmune conditions, particularly systemic lupus erythematosus (SLE), where persistent interferon activation contributes to disease pathogenesis and tissue damage.
Anifrolumab-FNIA is a human IgG1 kappa monoclonal antibody that blocks type I interferon signaling by binding to IFNAR1, preventing receptor-mediated downstream signaling. This biosimilar antibody serves as a valuable research tool for investigating type I interferon biology, studying IFNAR1-mediated signaling pathways, and exploring therapeutic mechanisms in autoimmune disease models. It enables researchers to examine the role of interferon signaling in inflammation, immune regulation, and disease progression.
Email: support@cusabio.com
Distributors Worldwide